Surrozen, Inc./DE (SRZN) Overview
- 1 Apr 2026: Period ending 30 Jun 2026; Estimate (m); Actual -0.41; Beat / miss (m).
- 1 Jan 2026: Period ending 31 Mar 2026; Estimate (m); Actual -11.65; Beat / miss (m).
- 1 Jul 2025: Period ending 30 Sept 2025; Estimate (m); Actual -8.36; Beat / miss (m).
- 1 Apr 2025: Period ending 30 Jun 2025; Estimate (m); Actual 2.55; Beat / miss (m).
Stock Price Chart
View more →Blue: Split-adjusted close · Orange: Cumulative dividend-reinvested close
Logarithmic scale. Both lines share the same starting value for the selected range.
- Last close
- $30.83
- Previous close
- $31.98
- Change
- -$1.15
- Change (%)
- -3.60%
- Close date
- 2026-11-06
- Previous close date
- 2026-09-29
- Open
- (m)
- Day high
- (m)
- Day low
- (m)
- Last session volume
- (m)
- Last session value
- (m)
- Currency
- USD
- Price basis
- split-adjusted
- Volume basis
- (m)
Performance
View more →Cumulative total returns · 2026-09-29
YTD
- SRZN
- +41.50%
- S&P 500
- (m)
1 year
- SRZN
- +174.27%
- S&P 500
- (m)
3 years
- SRZN
- +335.10%
- S&P 500
- (m)
5 years
- SRZN
- -69.84%
- S&P 500
- (m)
Earnings trends
View more →Earnings per share
USD / share · As filed
30 Jun 2026 ○ Estimate (m) ● Actual -0.41
Comparison details
| Period start | Period ending | Estimate | Actual | Beat / miss | Report date |
|---|---|---|---|---|---|
| 1 Apr 2026 | 30 Jun 2026 | (m) | -0.41 | (m) | (m) |
| 1 Jan 2026 | 31 Mar 2026 | (m) | -11.65 | (m) | (m) |
| 1 Jul 2025 | 30 Sept 2025 | (m) | -8.36 | (m) | (m) |
| 1 Apr 2025 | 30 Jun 2025 | (m) | 2.55 | (m) | (m) |
| 1 Jan 2025 | 31 Mar 2025 | (m) | -7.43 | (m) | (m) |
31 Dec 2025 ○ Estimate (m) ● Actual -32.37
Comparison details
| Period start | Period ending | Estimate | Actual | Beat / miss | Report date |
|---|---|---|---|---|---|
| 1 Jan 2025 | 31 Dec 2025 | (m) | -32.37 | (m) | (m) |
| 1 Jan 2024 | 31 Dec 2024 | (m) | -21.67 | (m) | (m) |
| 1 Jan 2023 | 31 Dec 2023 | (m) | -21.33 | (m) | (m) |
| 1 Jan 2022 | 31 Dec 2022 | (m) | -15.56 | (m) | (m) |
| 1 Jan 2021 | 31 Dec 2021 | (m) | -2.21 | (m) | (m) |
(m)
Revenue vs. Earnings
USD
30 Jun 2026 ■ Revenue 5.00M ■ Earnings 50.18M — Profit margin 1003.54%
31 Dec 2025 ■ Revenue 3.48M ■ Earnings -242.03M — Profit margin -6960.77%
Analyst insights
View more →| Ratings | Buy | Hold | Sell | Other ratings | Last Close | Average Target | Upside | High Target | Low Target |
|---|---|---|---|---|---|---|---|---|---|
| (m) | (m) | (m) | (m) | (m) | $30.83 | (m) | (m) | (m) | (m) |
Recent news
View more →(m)
YouTube videos mentioning SRZN
View more →(m)
Statistics
View more →Retained observations as of 2026-11-11; financial period ending 30 Jun 2026.
- Forward P/E
- (m)
- PEG ratio · 5-year expected
- (m)
- Shares held by insiders
- (m)
- Insider transactions · change (%)
- (m)
- Shares held by institutions
- (m)
- Institutional transactions · change (%)
- (m)
- Diluted EPS · 12 month
- (m)
- EPS estimate · next quarter
- (m)
- EPS estimate · next year
- (m)
- EPS growth · current annual estimate
- (m)
- EPS growth · next annual estimate
- (m)
- EPS growth · next 5 years expected
- (m)
- EPS growth · past 3 years annualized
- (m)
- EPS growth · past 5 years annualized
- (m)
- EPS change · 12 months vs prior year
- (m)
- EPS change · latest quarter vs previous quarter
- (m)
- Latest earnings report date
- (m)
- EPS surprise · latest reported quarter
- (m)
- Net income · 12 month
- $-332.13M
- Operating margin · 12 months
- -385.28%
- Profit margin
- -2885.33%
- Return on assets · 12 month
- -304.28%
- Named executive and board stock awards · latest fiscal year
- (m)
- Index membership
- (m)
- Employees
- 59.00
- IPO date
- (m)
- Options available
- (m)
- Shortable
- (m)
- Analyst recommendation
- (m)
- Analyst target price
- (m)
- Price volatility · week
- (m)
- Price volatility · month
- (m)
- Average true range · 14 sessions
- (m)
- Relative strength index · 14 sessions
- (m)
- Relative volume
- (m)
- Average daily volume
- 855.15K
- Latest session volume
- (m)
- Last session value
- (m)
- 30 days ago session value
- (m)
- 1 year ago session value
- (m)
- Number of trades
- (m)
- Total return · week
- 81.70%*
- Total return · month
- 42.64%*
- Total return · quarter
- 24.34%*
- Total return · half year
- 10.66%*
- Total return · year to date
- 41.50%*
- Total return · 1 year
- 174.27%*
- Total return · 3 years
- 335.10%*
- Total return · 5 years
- -69.84%*
- Market cap
- (m)
- Book value per share · latest quarter
- (m)
- Price / cash · latest quarter
- (m)
- Enterprise value
- (m)
- Enterprise value / revenue
- (m)
- Enterprise value / EBITDA
- (m)
- Dividend · 12 months per share
- (m)
- Dividend ex-date
- (m)
- Next dividend ex-date
- (m)
- Next dividend amount per share
- (m)
- Dividend growth · 3 years annualized
- (m)
- Dividend growth · 5 years annualized
- (m)
- R&D / revenue · 12 months
- 300.38%
- Revenue · 12 month
- $11.51M
- Revenue growth · past 3 years annualized
- (m)
- Revenue growth · past 5 years annualized
- (m)
- Revenue change · 12 months vs prior year
- (m)
- Revenue change · latest quarter vs previous quarter
- (m)
- Revenue surprise · latest reported quarter
- (m)
- Operating cash flow · 12 months
- $-34.76M
- Free cash flow · 12 months (USD)
- $-34.98M
- Levered free cash flow · 12 month
- (m)
- Debt / equity · latest quarter
- (m)
- Long-term debt / equity · latest quarter
- (m)
- Return on equity · 12 month
- (m)
- Return on invested capital · 12 months
- (m)
- Previous close
- (m)
- Latest closing price
- (m)
- Latest session change (%)
- (m)
- 52-week high
- (m)
- 52-week low
- (m)
- Price vs 20-session moving average
- (m)
- Price vs 50-session moving average
- (m)
- Price vs 200-session moving average
- (m)
- Float shares
- (m)
- Short float (%)
- (m)
- Short ratio (days to cover)
- (m)
- Short interest (shares)
- (m)
Five-year projected P/E and P/S repeat the preceding five-year EPS and revenue CAGR, holding current price and market cap constant. Hover a calculated row for its formula. Net assets = assets − debt − payables − deferred revenue − obligations due within 1 year − obligations due after 1 year.
Holders breakdown
View more →| Breakdown | Ownership |
|---|---|
| (m) | Shares held by all insiders |
| (m) | Shares held by institutions |
| (m) | Float held by institutions |
| (m) | Institutions holding shares |
Other holders
(m)
Insider holders
(m)
Top institutional holders
(m)
Top mutual fund holders
(m)
Surrozen, Inc./DE Overview
View more →(m)
(m)
- SEC CIK
- 1824893
- Industry (SIC)
- 2836 Biological Products, (No Diagnostic Substances)
- Country of operation
- United States
- Business address
- 171 OYSTER POINT BLVD, SUITE 400, SOUTH SAN FRANCISCO, California, 94080, United States
- Fiscal year end
- 1231
- Phone
- 650-475-2820
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |